Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Qulipta on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Qulipta (atogepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for the preventive treatment of migraine in adults.
Qulipta blocks the CGRP receptor, preventing CGRP, a protein involved in the transmission of migraine pain signals, from binding and triggering the cascade of events associated with migraine attacks. This helps reduce the frequency of migraine days.
Qulipta is approved for adults with either episodic migraine (fewer than 15 headache days per month) or chronic migraine (15 or more headache days per month), as preventive rather than acute treatment.
For episodic migraine, the recommended dose is 10 mg, 30 mg, or 60 mg orally once daily. For chronic migraine, the recommended dose is 60 mg orally once daily.
Qulipta does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Hypersensitivity reactions, including anaphylaxis and dyspnea, have been reported and may occur even days after dosing. Qulipta should be discontinued if a serious hypersensitivity reaction occurs.
New-onset or worsening hypertension has been reported, in some cases requiring hospitalization. Blood pressure should be monitored, particularly in patients with pre-existing hypertension.
New-onset or worsening Raynaud's phenomenon, including serious outcomes requiring treatment, has been reported with CGRP-targeting therapies such as Qulipta.
Dose adjustment may be required in patients with moderate to severe hepatic impairment; a treating physician should assess this before starting treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Qulipta is manufactured and marketed by AbbVie Inc. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating neurologist confirming migraine diagnosis and frequency. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for migraine prevention, Qulipta is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Qulipta directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Qulipta should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Qulipta through NPP's regulated import pathway, with neurology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support neurology care coordination and documentation for Qulipta access.
Delhi's major hospitals assist patients with prescription support and documentation for Qulipta.
Bangalore's specialist network offers access coordination for eligible migraine patients seeking Qulipta.
Chennai-based neurology specialists coordinate Qulipta access alongside comprehensive migraine care.
Hyderabad's care institutions support patients pursuing Qulipta therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Qulipta.
Pune-based specialists assist with prescription support and Qulipta treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Qulipta.
Kochi's specialist units assist patients with the documentation needed for Qulipta access.
Chandigarh's care centers support Qulipta treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Qulipta access process.
Lucknow-based centers assist patients pursuing Qulipta therapy.
Bhubaneswar's institutions support access to Qulipta for eligible patients.
Guwahati's specialists help coordinate Qulipta access for patients across the Northeast.
Patients in other cities across India can also access Qulipta through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
